2013 has been a big year for Abbott Labs (NYSE: ABT ) . The company's charged ahead into its new post-pharmaceutical future, and today's earnings report marked the first time that investors had a chance to see how well Abbott's adapting to the radical shake-up. Fortunately, Abbott performed well: The company's earnings per share minus one-time items just topped analyst expectations, and sales grew 2% year-over-year. The pharmaceuticals spinoff took its toll on Abbott's net profit, but that was to be expected.
With earnings on record, here are the three things you should take away from Abbott's first report card of its new life.
Nutritional sales are surging
The new Abbott's nutritionals branch is its biggest division by sales, so it's a good thing this unit performed well this past quarter.
Sales of nutritional items grew 9% overall, keeping Abbott's foundation on an upward course. Divisional revenue grew 9% in the U.S. and 8% internationally last year, and investors should expect growth to continue here into the future. Abbott has turned nutritionals into its new foundation, and it will have to compensate for slower-growing divisions such as generic drugs and medical devices.
Hot Media Companies For 2015: CNOOC Limited(CEO)
CNOOC Limited, through its subsidiaries, engages in the exploration, development, production, and sale of crude oil, natural gas, and other petroleum products. The company?s oil and natural gas properties are located in offshore China, which include Bohai Bay, western south China Sea, eastern south China Sea, and east China Sea, as well as in Indonesia, Iraq, and other regions in Asia; and Oceania, Africa, North America, and South America. As of December 31, 2010, the company had net proved reserves of approximately 2.99 billion barrels-of-oil equivalent, including approximately 1.92 billion barrels of crude oil and 6,458.3 billion cubic feet of natural gas. It also provides bond issuance services; and has a joint venture with Bridas Energy Holdings. CNOOC Limited was founded in 1982. The company is headquartered in Central, Hong Kong, and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange. CNOOC Limited is a subsidiary of China National Of fshore Oil Corporation.
Advisors' Opinion:- [By Stephan Dube]
Athabasca's most notable producers:
Suncor Energy (SU) (Part 1), see article here.Suncor Energy (Part 2), see article here.Athabasca Oil (ATHOF.PK), see article here.Canadian Natural Resources, see article here.Imperial Oil, see article here.Cenovus Energy (CVE), see article here.MEG Energy (MEGEF.PK), see article here.Devon Energy, see article here.Royal Dutch Shell, see article here.Ivanhoe Energy (IVAN), see article here.Nexen (CNOOC) (CEO), see article here.An analysis of the current operations of the company will be examined with the objective to provide the most complete information available to potential investors before deciding to seize the opportunity that the 54,132 square miles of the Carbonate Triangle has to offer. Let's start by introducing Athabasca, a famous and most prolific region in the Canadian oil sands as well as one of the largest reserve in the world.
- [By Rich Smith]
In a deal being described as its biggest international bond offering ever, and the largest dollar bond offering in all of Asia in at least the past decade, Chinese oil major CNOOC (NYSE: CEO ) announced Friday that it will issue $4 billion worth of dollar-denominated bonds. These include:�$750 million worth of 1.125% guaranteed notes due 2016,�$750 million worth of 1.750% guaranteed notes due 2018,�$2 billion in 3.000% guaranteed notes due 2023, and�$500 million in 4.250% guaranteed notes due 2043.
- [By Arjun Sreekumar]
Initially, exploration activity in the Arctic was confined primarily to Western oil majors. But recently, the China National Offshore Oil Corporation, better known as CNOOC (NYSE: CEO ) , became the first Chinese oil company to make a play for Arctic oil. Let's take a closer look at why China has become increasingly interested in the Arctic frontier's vast resource potential.
- [By Chris Mydlo]
CNOOC Ltd. (CEO) is trading at a low P/S ratio of 1.60, near its 10-year low of 1.42. The company explores for, develops, produces, and sells crude oil, natural gas, and other petroleum products. It is held by nine gurus we follow.
Top 10 Sliver Companies To Watch For 2014: Cannabusiness Group Inc (CBGI)
Cannabusiness Group Inc, formerly Muscle Warfare International Inc, incorporated on June 24, 2005, focuses to research, evaluate, and acquire profitable private firms in the business segments of entertainment, technology, medical, energy, and business services for the benefit of its shareholders. The Company's subsidiaries include American West Baseball League and Elite Representation Associates. In April 2013, it announced acquiring 100% of Muscle Warfare, Inc. In July 2013, the Company announced the acquisition of a company that develops, manufactures, and markets sports nutrition products for athletes around the world in all sports, including both professional and amateur enthusiasts.
Elite Representation Associates is an athlete/coach management and marketing agency. The American West Baseball League is a professional, independent baseball organization located primarily in the Southwest United States. It operates in cities not served by major or minor league baseball team.
Advisors' Opinion:- [By Dan Burrows]
From questions regarding the accuracy of publicly-available information about these companies��operations to potential illegal activity, these marijuana stocks have incurred the wrath of federal regulators for good reason:
GrowLife (PHOT) FusionPharm (FSPM) CannaBusiness Group (CBGI) Advanced Cannabis Solutions (CANN) Petrotech Oil and Gas (PTOG) Marijuana Stocks Asking for TroubleBut it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:
Top 10 Sliver Companies To Watch For 2014: African Barrick Gold PLC (ABGLF)
African Barrick Gold plc (ABG) is a United Kingdom-based company. The Company is a gold producer in Tanzania. Its operations include exploration and development to mine construction and operation. ABG has resources of approximately 32 million ounces of gold. The Company has three producing mines, all located in northwest Tanzania: Bulyanhulu, Buzwagi and North Mara, and several exploration projects at various stages of development in Tanzania and Kenya. Bulyanhulu is an underground gold mine. Buzwagi is an open pit gold mine. North Mara is an open pit gold mine consisting of three open pit deposits. Advisors' Opinion:- [By Ben Levisohn]
Over the last several months, ABX has been divesting non-core assets. Starting in mid-2013, the company sold its non-core energy assets. Since then, focus has been on selling Australian gold assets. As we have stated previously, we believe the company will continue to sell noncore assets, focusing primarily on its interests in North America. Barrick had been previously seeking a suitor for its 74% interest in African Barrick (ABGLF); to date, the company remains unsuccessful in disposition of the ABG interest. In addition, we would not be averse to seeing Barrick sell off some or all of its copper assets, if they can get the right price.
Top 10 Sliver Companies To Watch For 2014: BioTime Inc (BTX)
BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.
HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.
The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.
Human Embryonic Stem Cell Lines for Research Use
Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.
The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.
Human Embryonic Progenitor Cells
Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.
Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.
hES Cells Carrying Genetic Diseases
The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).
ESpan Cell Growth Media
The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.
ESpy Cell Lines
The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.
HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices
HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.
Advisors' Opinion:- [By John Udovich]
Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:
Top 10 Sliver Companies To Watch For 2014: Marin Software Inc (MRIN)
Marin Software Incorporated, incorporated on March 16, 2006, provides cloud-based digital advertising management platform to advertisers and agencies. The Company�� Revenue Acquisition Management platform is a software-as-a-service (SaaS), analytics, workflow, and optimization solution for marketing professionals, enabling them to manage their digital advertising spend across search, display, social and mobile advertising channels. Its platform integrates with publishers, such as Baidu, Bing, Facebook, Google, Yahoo! and Yahoo! Japan, as well as Web analytics and ad-serving solutions, and key enterprise applications to enable marketers to measure the return on investment of their marketing programs.
The Company�� software platform serves as a system-of-record for advertising performance, revenue and conversion data and allows advertisers to correlate advertising spend to subsequent revenue outcomes or business events. It enables its customers to simultaneously run large-scale digital advertising campaigns across multiple publishers and channels, making it easy for marketers to create, publish, modify and optimize campaigns in real time.
Advisors' Opinion:- [By Evan Niu, CFA]
What: Shares of Marin Software (NYSE: MRIN ) got clobbered today, down by as much as 21% after the company reported earnings.
So what: Revenue in the first quarter totaled $17.2 million, which resulted in a non-GAAP net loss of $9.4 million, or $0.39 per share. The freshly public software maker saw gross margin decline to 57%, and its losses grew from a year ago. Investors obviously wanted more.
Top 10 Sliver Companies To Watch For 2014: Wolseley PLC (WOS)
Wolseley plc is a specialist trade distributor of plumbing and heating products to professional contractors and a supplier of building materials in North America, the United Kingdom and Continental Europe. The Company operates in seven segments: USA, UK, Canada, Nordic, France, Central and Eastern Europe, and Group. On September 1 2009, the Company acquired Decorative Product Source, Inc, a company engaged in the distribution and supply of construction materials and services. On January 8, 2010, the Company disposed of 100% of Wolseley Ireland Holdings Limited, which comprised all the Company's businesses in the Republic of Ireland and the Brooks business in Northern Ireland. In November 2011, the Company announced that it had completed the sale of its remaining interest in Stock Building Supply to The Gores Group. In April 2012, the Company sold its Brossette, the French Plumbing and Heating business to Saint Gobain. In October 2012, the Company acquired Davis & Warshow, Inc. Advisors' Opinion:- [By Inyoung Hwang]
Wolseley Plc (WOS) added 3.1 percent to 3,296 pence, its largest gain in more than five weeks. The world�� biggest distributor of plumbing and heating products said so-called trading profit in the 12 months through July climbed to 725 million pounds ($1.2 billion) from 665 million pounds a year earlier. Analysts had predicted earnings of 704 million pounds, according to the average of 20 estimates compiled by the company. Wolseley proposed a special dividend payout of 300 million pounds.
Top 10 Sliver Companies To Watch For 2014: Discount Dental Materials Inc (DDOO)
Discount Dental Materials, Inc. (DDM), incorporated on December 18, 2007, is a development-stage company. The Company focuses on selling disposable dental supply products at discount prices over the Internet. As of November 30, 2011, the Company had not generated any revenues.
The Company focuses on selling a limited number of products including burs (modern dental drills that can rotate at up to 800,000 revolutions per minute (rpm) and generally use hard metal rotary files). Dental burs come in a variety of shapes designed for specific applications. They are often made of steel with a tungsten carbide coating or of tungsten carbide entirely. The bur may also have a diamond coating), bearings, turbines and sterilization pouches. The Company uses a facility in Burbank, California to store and ship products.
The Company competes with Henry Schein and Patterson Dental.
Advisors' Opinion:- [By CRWE]
Today, DDOO remains (0.00%) +0.000 at $1.00 thus far (ref. google finance Delayed: 10:12AM EDT�June 25, 2013).
Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.
Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum
- [By CRWE]
Last Friday, DDOO previously surged (+5.00%) up +0.05 at $1.05 with 10,200 shares in play at the close (ref. google finance June 28, 2013 ��Close).
Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.
Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum
- [By CRWE]
Today, DDOO remains (0.00%) +0.000 at $1.05 thus far (ref. google finance Delayed:� 3:42PM EDT July 1, 2013).
Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. , previously reported that medical device product development company, Sonos Models, Inc. (��onos��, is set to complete the first prototypes of its medical device solution during the company�� first fiscal quarter, which begins July 1, 2013.
Cerebain�� President, Eric Clemons, stated, ��e are excited with the imminent completion of the first set of prototypes of our Medical Device Product for the treatment of Alzheimer�� Disease. Years of hard work and research will culminate with the introduction of these prototypes which will utilize the Omentum for the treatment of patients with this debilitating disease. With these prototypes, we are introducing a leading edge approach to the treatment of Alzheimer�� Disease.��/p>
No comments:
Post a Comment